Vendor comparison · 2026
BPC-157 vendors: 36 compared on COAs and price
Tissue & recoveryAlso known as Body Protection Compound 157, PL 14736
Evidence tier
Preclinical, thin human data
3 preclinical
- Vendors carrying it
- 36
- 34 with a listed price
- Vendors with checkable COAs
- 19
- 20 publish any certificate
- Lots tested
- 38
- 37 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 24 Sept 2026
- oldest 9 Oct 2025
- Laboratories named
- 11
- most often Freedom Diagnostics Testing
- Median label gap
- 5.2%
- 50% of lots within 5% of label
- Median purity
- 99.55%
- 38 of 38 lots at 99% or above
- Lowest price per mg
- $2.50
- peer median $5.50
- Publications located
- 223
- researched since 1992
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable BPC-157 testing in this index: 6 lots assayed by ILS Laboratories, the newest on 23 Sept 2026. The lowest listed price is $2.50 per mg at Origin Labs, against a peer median of $5.50. 36 vendors carrying BPC-157 are compared below. 19 publish at least one certificate naming a checkable laboratory, 38 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying BPC-157
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | $2.50 (46%) | 1 / 1 | Freedom Diagnostics Testing | 99.4% | 37.2% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $3.00 (55%) | 6 / 6 | ILS Laboratories | 99.6% | 4.0% | ||
| 3 | PeptidePlugs | 91.394% | $3.00 (55%) | 2 / 2 | Freedom Diagnostics Testing | 99.3% | 10.8% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 9198% | $4.00 (73%) | 2 / 2 | ILS Laboratories, Freedom Diagnostics Testing | 99.4% | 11.1% | ||
| 5 | Ascend ScienceISO/IEC 17025 | 88.694% | $4.90 (89%) | 0 | — | — | — | — | |
| 6 | Bench Grade Peptides | 86.589% | $3.90 (71%) | 3 / 3 | AV Analytics, Freedom Diagnostics Testing | 99.6% | 7.0% | ||
| 7 | Hydro Research PeptidesISO/IEC 17025 | 84.189% | $4.00 (73%) | 2 / 2 | ILS Laboratories | 99.7% | 8.7% | ||
| 8 | Stealth Research Labs | 83.991% | $5.00 (91%) | 1 / 1 | Bioviridian Inc. | 99.7% | 2.4% | ||
| 9 | Ascension Peptides | 83.689% | $4.90 (89%) | 1 / 1 | MZ Biolabs | 99.8% | 0.9% | ||
| 10 | One Aminos | 83.689% | $5.00 (91%) | 1 / 1 | United Laboratories | 99.5% | 2.0% | ||
| 11 | Simple Peptide | 79.192% | $5.50 (100%) | 3 / 3 | Freedom Diagnostics Testing | 99.3% | 11.7% | ||
| 12 | NeuroLabs Research | 7991% | $6.00 (109%) | 1 / 1 | Freedom Diagnostics Testing | 99.2% | 21.2% | ||
| 13 | Transition Biotech | 78.991% | $4.50 (82%) | 1 / 1 | Kovera Labs | 99.6% | 10.7% | ||
| 14 | Modern AminosISO/IEC 17025COAs need an account | 76.297% | $6.80 (124%) | 2 / 2 | Freedom Diagnostics Testing | 99.5% | 18.8% | ||
| 15 | Prime PeptidesISO/IEC 17025 | 75.796% | $5.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 16 | CuroISO/IEC 17025 | 74.897% | $8.00 (146%) | 1 / 1 | BTLabs | 99.6% | 24.0% | ||
| 17 | Protide HealthAge-gated COAs | 74.592% | $6.50 (118%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 8.3% | ||
| 18 | Vertex Labs | 74.272% | $2.67 (49%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Evo Labs Research | 74.187% | $5.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Good Science Bio | 71.171% | $4.50 (82%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Northline LabsISO/IEC 17025 | 69.595% | $8.80 (160%) | 4 / 4 | ILS Laboratories, Horizon Analytical | 99.3% | 0.8% | ||
| 22 | Eternal Peptides | 68.963% | $3.60 (66%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Evolve Peptides | 65.468% | $5.49 (100%) | 0 | — | — | — | — | no reportVisit site |
| 24 | GenX Peptides | 6469% | $6.00 (109%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Disguised Alpha | 62.766% | $5.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 26 | True Research Labs | 60.768% | $6.40 (116%) | 0 | — | — | — | — | no reportVisit site |
| 27 | Licensed Peptides | 60.687% | $10.40 (189%) | 1 / 1 | Janoshik Analytical | 99.9% | 13.2% | ||
| 28 | Improved Peptides | 59.887% | $7.50 (136%) | 0 / 1 | Not named | 99.2% | 18.1% | ||
| 29 | Vial Drop Labs | 59.474% | — | 3 / 3 | KMD Analytical (KMD Group LLC) | 100.0% | 0.7% | ||
| 30 | Peptime | 55.557% | — | 1 / 1 | Freedom Diagnostics Testing | 99.1% | 13.8% | ||
| 31 | Paramount Peptides | 54.771% | $9.35 (170%) | 0 | — | — | — | — | no reportVisit site |
| 32 | BioLongevity Labs | 54.572% | $9.33 (170%) | 0 | — | — | — | — | no reportVisit site |
| 33 | Extreme Peptides | 52.280% | $9.80 (178%) | 0 | — | — | — | — | no reportVisit site |
| 34 | Sports Technology LabsAge-gated COAs | 50.771% | $22.80 (250%) | 0 | — | — | — | — | no reportVisit site |
| 35 | Biotech Peptides | 49.160% | $9.20 (167%) | 0 | — | — | — | — | no reportVisit site |
| 36 | Mile High Compounds | 47.591% | $12.50 (227%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of BPC-157 is on file. All 38 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
38 of 38 lots at 99% or above; median 99.55%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 17 |
| ≥99.5% | 21 |
50% of lots within 5% of the labelled mass; median gap 5.2%.
| Range | lots |
|---|---|
| ≤2% | 11 |
| 2–5% | 8 |
| 5–10% | 4 |
| 10–20% | 12 |
| >20% | 3 |
34 vendors, $2.50 to $22.80; median $5.50.
| Range | vendors |
|---|---|
| $0–$5.00 | 12 |
| $5.00–$10.00 | 19 |
| $10.00–$15.00 | 2 |
| $15.00–$20.00 | 0 |
| $20.00–$25.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 13 | 9 | 34% | Public lookup |
| ILS LaboratoriesUS | 12 | 4 | 32% | Public lookup |
| KMD Analytical (KMD Group LLC)US | 3 | 1 | 8% | Public lookup |
| AV Analytics | 2 | 1 | 5% | No public lookup found |
| Bioviridian Inc.US | 1 | 1 | 3% | Public lookup |
| BTLabs | 1 | 1 | 3% | No public lookup found |
| Horizon Analytical | 1 | 1 | 3% | No public lookup found |
| Janoshik AnalyticalCZ | 1 | 1 | 3% | Public lookup |
| Kovera Labs | 1 | 1 | 3% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 3% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 3% | Public lookup |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1992 — 34 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
223 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.5% across 38 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.29 pts purity across lots, mean label deviation 8.8%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
36 of 36 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
37 of 38 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is BPC-157?
A synthetic peptide of fifteen amino acids, derived from a sequence identified in human gastric juice. It is supplied as a lyophilised powder and is one of the most widely listed compounds across the vendors in this index.
Studied in published research for tissue repair — tendon, ligament, muscle and gut healing.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is predominantly preclinical and conducted in animal models. Reported endpoints in that literature concern tissue repair and gastrointestinal models. PepIndex does not evaluate or summarise clinical significance and does not describe administration.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel, Switzerland) (2025)
Peer-reviewed article indexed in PubMed, published in Pharmaceuticals (Basel, Switzerland) (2025).
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell and tissue research (2019)
Peer-reviewed article indexed in PubMed, published in Cell and tissue research (2019).
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Alternative therapies in health and medicine (2021)
Peer-reviewed article indexed in PubMed, published in Alternative therapies in health and medicine (2021).
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — Frontiers in pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2021).
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS journal : the musculoskeletal journal of Hospital for Special Surgery (2025)
Peer-reviewed article indexed in PubMed, published in HSS journal : the musculoskeletal journal of Hospital for Special Surgery (2025).
- BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Current pharmaceutical design (2018)
Peer-reviewed article indexed in PubMed, published in Current pharmaceutical design (2018).
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — Current reviews in musculoskeletal medicine (2025)
Peer-reviewed article indexed in PubMed, published in Current reviews in musculoskeletal medicine (2025).
- Pentadecapeptide BPC 157 and the central nervous system — Neural regeneration research (2022)
Peer-reviewed article indexed in PubMed, published in Neural regeneration research (2022).
Indexed studiespreclinical only of 3
- Preclinical rodent work on BPC-157 and tendon healing — Animal
The listed literature reports outcomes in rodent tendon-injury models. Endpoints are histological and biomechanical measurements in animals; no human endpoint is reported in this body of work.
- Preclinical rodent work on BPC-157 in gastrointestinal injury models — Animal
The listed literature reports mucosal outcomes in induced gastrointestinal lesion models in rodents. The originating sequence was identified in gastric juice; the material sold under this name is synthetic.
- In vitro work on BPC-157 and fibroblast activity — In vitro
Cell-culture work examining fibroblast migration and proliferation. In vitro results describe cell behaviour in a dish and do not establish an effect in a living organism of any species.
Evidence digest
What the research on BPC-157 actually shows
The published BPC-157 literature is preclinical. It consists of rodent injury models and cell-culture work; there are no controlled human trials in the indexed literature. That is the single most important thing to know about this compound, because vendor copy routinely describes rodent findings in language that implies a human effect. Animal results are a reason to run a human trial, not a substitute for one.
5 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.